Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZJK
|
|||
| Former ID |
DAP000428
|
|||
| Drug Name |
Ardeparin
|
|||
| Synonyms |
Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Deep vein thrombosis [ICD-11: BD71] | Approved | [1] | |
| Venous thrombosis [ICD-11: BA43; ICD-10: I24.0] | Approved | [1], [2] | ||
| Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 3 | [3] | ||
| Venous thromboembolism [ICD-11: BD72; ICD-9: 453] | Phase 3 | [4], [5] | ||
| Therapeutic Class |
Anticoagulants
|
|||
| Company |
Celcius Laboratories
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C26H42N2O37S5
|
|||
| Canonical SMILES |
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
|
|||
| InChI |
1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
|
|||
| InChIKey |
HTTJABKRGRZYRN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 9005-49-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6535120, 8156229, 10530334, 29227437, 51073550, 57325241, 80708216, 85084882, 85086575, 91105364, 104318751, 125340739, 125363823, 126676137, 127270292, 127270293, 127270294, 127270295, 127270296, 127270297, 127270298, 127270299, 127270300, 127270301, 127270302, 127270303, 127270304, 127270305, 127270306, 127270307, 127270308, 127270309, 127270310, 127270311, 127270312, 127270313, 127270314, 127270315, 127270316, 127270317, 127270318, 127270319, 127270320, 127270321, 127270322, 127270323, 127270324, 127270325, 127270326, 127270327
|
|||
| ADReCS Drug ID | BADD_D00772 ; BADD_D02222 ; BADD_D02459 | |||
| SuperDrug ATC ID |
B01AB01; B01AB01; B01AB01; B01AB04; B01AB05; B01AB05; B01AB06; B01AB07; B01AB07; B01AB08; B01AB10; B01AB12; C05BA03; C05BA03; C05BA03; S01XA14
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Antithrombin-III (ATIII) | Target Info | Modulator | [6] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacologic profile of certoparin. Expert Opin Investig Drugs. 1999 Mar;8(3):315-27. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6811). | |||
| REF 3 | Clinical pipeline report, company report or official report of Emisphere Technologies Inc. | |||
| REF 4 | Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. | |||
| REF 5 | Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011 Apr 1;117(7):1334-49. | |||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.